Modern aspects of diabetes mellitus type 2 treatment in cardiology practice (in the context of EASD/ADA consensus and Russian guidelines)

Cover Page

Cite item

Full Text

Abstract

The article presents the importance of the problem of diagnostics and treatment of patients with diabetes mellitus (DM) type 2 in the light of steady increase of the prevalence of the disorder and its complications. Chronic hyperglycemia is a leading factor of cardiovascular disorders development associated with damage of eyes, kidneys, cardiac vessels, brain, and lower extremities arteries that results in disability and mortality of patients with DM type 2 and defines its social significance. The article provides definition of DM concept and classification, characterizes DM type 2 and other glycemic disorders diagnostic criteria. It is outlined that glycated hemoglobin (6.5% and more) is the diagnostic criterion for DM type 2. Special attention is given to glycemia self-control with the use of Contour™ Plus One glucometer, the distinguishing feature of which is the possibility of synchronization with mobile application Contour™ Diabetes. Therapeutic goals of DM type 2 treatment are defined according to ADA/EASD-2018 consensus (American Diabetes Association/ European Association for the Study of Diabetes) and Russian Association of Endocrinologists algorithms (2019). Recommendations for personalization of antihyperglycemic drugs choice in various clinical cases in consideration of rational drug combinations are given. Particular advantages of treatment using Russian guidelines are discussed.

About the authors

Anna G. Evdokimova

A.I.Yevdokimov Moscow State University of Medicine and Dentistry

Email: aevdokimova@rambler.ru
д-р мед. наук, проф. каф. внутренних болезней Moscow, Russia

Anna A. Golikova

A.I.Yevdokimov Moscow State University of Medicine and Dentistry

D. Sci. (Med.), Prof. Moscow, Russia

Raisa I. Striuk

A.I.Yevdokimov Moscow State University of Medicine and Dentistry

D. Sci. (Med.), Prof. Moscow, Russia

Elena G. Lobanova

A.I.Yevdokimov Moscow State University of Medicine and Dentistry

D. Sci. (Med.), Prof. Moscow, Russia

References

  1. Глобальный доклад по диабету ВОЗ-2016. @@WHO 2016 Global Diabetes Report
  2. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой, А.Ю.Майорова. Вып. 9. М.: Принт, 2019. DOI: 10.143.41/DM22131 @@Algorithms for specialized medical care for patients with diabetes. Pod red. I.I.Dedova, M.V.Shestakovoi, A.Iu.Maiorova. Vyp. 9. Moscow: Print, 2019. DOI: 10.143.41/DM22131
  3. Осложнение сахарного диабета: лечение и профилактика. Под ред. И.И.Дедова, М.В.Шестаковой М.: Медицинское информационное агентство, 2017. @@Complications of diabetes: treatment and prevention. Pod red. I.I.Dedova, M.V.Shestakovoi Moscow: Meditsinskoe informatsionnoe agentstvo, 2017
  4. Davies M.Y, Alessio D.A, Fradkin J et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). EASD, ADA 2018. Diabetes Care 2018; 41: 2669-701. doi: 10.2337/dci18-0033
  5. Контур плюс. Руководство пользователя. Байер, 2013. @@Contour plus. User's manual. Baier, 2013
  6. Marso S.P, Daniels G.H, Brown-Fradsen V et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Eng J Med 2016; 275 (4): 311-22. doi: 10.1056/NEJMed16008827
  7. Wanner C, Lachin J.M, Inzucchi S.E et al. EMPA-REG OUTCOME Investigators. Circulation 2018; 137 (2): 119-29. doi: 10.1161/CIRCULATIONAHA.117.028268

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies